2.55
-0.10 (-3.60%)
| 前收盘价格 | 2.64 |
| 收盘价格 | 2.60 |
| 成交量 | 266,106 |
| 平均成交量 (3个月) | 794,325 |
| 市值 | 205,054,832 |
| 市盈率 (P/E TTM) | 11.07 |
| 预期市盈率 (P/E Forward) | 55.87 |
| 价格/销量 (P/S) | 2.82 |
| 股市价格/股市净资产 (P/B) | 3.16 |
| 52周波幅 | |
| 利润日期 | 12 Nov 2026 |
| 营业毛利率 | 6.54% |
| 营业利益率 (TTM) | -40.99% |
| 稀释每股收益 (EPS TTM) | 0.050 |
| 季度收入增长率 (YOY) | 169.80% |
| 总债务/股东权益 (D/E MRQ) | 11.58% |
| 流动比率 (MRQ) | 2.49 |
| 营业现金流 (OCF TTM) | 8.67 M |
| 杠杆自由现金流 (LFCF TTM) | -3.29 M |
| 资产报酬率 (ROA TTM) | 3.53% |
| 股东权益报酬率 (ROE TTM) | 10.42% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Protalix BioTherapeutics, Inc. | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -0.5 |
| 相对估值 | NA |
| 财务健康 | 2.5 |
| AI Insight | NA |
| 平均 | 0.06 |
|
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 10.39% |
| 机构持股比例 | 10.22% |
该时间范围内无数据。
该时间范围内无数据。
AI 技术分析
打开“技术”标签以生成最新分析。
投资组合